| Authors: |
Ledermann JA; Cancer Research UK and UCL Cancer Trials Centre, University College London and UCL Hospitals, London, UK. Electronic address: j.ledermann@ucl.ac.uk., Embleton AC; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Raja F; University College London Hospitals, London, UK., Perren TJ; St James's Institute of Oncology and Leeds Institute of Cancer Medicine and Pathology, Leeds, UK., Jayson GC; Christie Hospital and University of Manchester, Manchester, UK., Rustin GJS; Mount Vernon Cancer Centre, Northwood, UK., Kaye SB; Royal Marsden Hospital, London, UK., Hirte H; Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada., Eisenhauer E; Canadian Cancer Trials Group (CCTG) and Queen's University, Kingston, ON, Canada., Vaughan M; Christchurch Hospital, Christchurch, New Zealand., Friedlander M; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia., González-Martín A; Spanish Group for Investigation in Ovarian Cancer (GEICO) and MD Anderson Cancer Center Madrid, Madrid, Spain., Stark D; University of Leeds, Leeds, UK., Clark E; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Farrelly L; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Swart AM; University of East Anglia, Norwich, UK., Cook A; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Kaplan RS; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Parmar MKB; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK. |
